Stocks & Investing
Stocks and Investing
Stocks and Investing
Thu, September 24, 2009
Wed, September 23, 2009 Interleukin Genetics (ILI) Daily Short Sale Trading Volume Through 9-22-09
September 23, 2009 / M2 PRESSWIRE / BUYINS.NET, www.buyins.net, has reviewed the NYSE, NASDAQ, BX, CHX and NSX Daily Short Volume Report through Tuesday, September 22nd, 2009 and come to the following statistical conclusions. The chart below shows aggregated daily short volume in Interleukin Genetics (AMEX: ILI) for August through September 22, 2009. To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://www.buyins.net.
Date Short Volume Total Volume Percent
9/22/2009 1,900 25,400 7.48%
9/21/2009 400 50,900 0.79%
9/18/2009 0 16,400 0.00%
9/17/2009 0 27,100 0.00%
9/16/2009 300 15,800 1.90%
9/15/2009 797 18,800 4.24%
9/14/2009 1,500 140,700 1.07%
9/11/2009 0 3,400 0.00%
9/10/2009 2,300 26,300 8.75%
9/9/2009 2,500 68,200 3.67%
9/8/2009 0 18,500 0.00%
9/4/2009 200 0.00%
9/3/2009 200 1,000 20.00%
9/2/2009 16,100 0.00%
9/1/2009 2,100 14,200 14.79%
8/31/2009 1,900 63,600 2.99%
8/28/2009 2,400 0.00%
8/27/2009 0 12,500 0.00%
8/26/2009 800 18,600 4.30%
8/25/2009 0 19,800 0.00%
8/24/2009 1,500 21,100 7.11%
8/21/2009 0 23,500 0.00%
8/20/2009 3,100 45,900 6.75%
8/19/2009 0 4,200 0.00%
8/18/2009 700 41,400 1.69%
8/17/2009 5,400 115,800 4.66%
8/14/2009 300 6,000 5.00%
8/13/2009 0 20,900 0.00%
8/12/2009 2,000 0.00%
8/11/2009 0 3,300 0.00%
8/10/2009 0 300 0.00%
8/7/2009 0 11,900 0.00%
8/6/2009 600 13,400 4.48%
8/5/2009 202 7,100 2.85%
8/4/2009 6,000 12,300 48.78%
8/3/2009 800 24,100 3.32%
Total 33,299 913,100 3.65%
In late October 2008 the SEC updated Regulation SHO requiring that all short sellers must locate, borrow and deliver any shares they have shorted, no exceptions, by T+3 settlement date. If not, a buy-in must be forced by the broker dealer that the short seller transacted through by the opening of the market on T+4. Since a company first appears on the naked short list when short sellers have been failing to deliver for 5 consecutive trading days, stocks should theoretically never be on the naked short list again. BUYINS.NET will monitor the exchangesa� naked short lists daily and issue an alert and notify the SEC and FINRA should short sellers fail to deliver on any short sales.
Reg SHO Rule 204 (i) requires brokers to deliver shares on long and short sales of publicly traded equity securities by settlement date, (ii) continues to require brokers to close-out fails to deliver by the beginning of trading on T+4 for short sales and T+6 for long sales, (iii) precludes clearing brokers and their introducing brokers from selling short a security, other than on a pre-borrowed basis, if a fail to deliver in that security is not timely closed out until the fail is closed out and that close-out transaction settles, (iv) allows clearing brokers to allocate fails to introducing brokers and (v) continues to permit brokers to rely upon pre-fail credit to satisfy Rule 204's close-out requirement to avoid the pre-borrow requirements when a fail at a clearing broker has not been closed out. However, the SEC liberalized certain of these provisions in several regards. For example, permanent Rule 204 now allows a broker to close-out a fail on a long sale by borrowing the security, whereas Rule 204T had only permitted closing out long fails by buying-in, which should alleviate some of the buy-in risk for investors that experience long fails. Similar relief was extended to close-outs for market maker fails, so that a fail from a bona fide market making transaction (including short and long fails) can now be closed out by the beginning of trading on T+6 by borrowing the security. Further, Rule 204 now permits a broker to borrow securities to obtain pre-fail credit for early close-outs, whereas temporary Rule 204T only permitted pre-fail credit to be obtained by purchases of securities.
The SEC refused requests to extend the close-out deadline for fails to deliver to the close of business on the close-out deadline, choosing instead to retain the requirement that all fails be closed out by the beginning of trading on the applicable close-out deadline. The Commission also rejected requests for a fail to deliver exception that would have provided an exception from the close-out requirements if a clearing broker's fail position was below a certain amount but said that it would continue to monitor whether a de minimis or odd lot exception could be warranted.
Interleukin Genetics, Inc. (AMEX: ILI) focuses on developing, acquiring, and commercializing personalized health products that can help individuals improve and maintain their health through preventive measures. The company uses functional genomics to help in the development of risk assessment tests based on the genetic variations in people. It also develops and markets nutritional products. Genetic Test Products Gensona Genetic Tests: The company has research agreements with Alticor Inc. to develop certain genetic tests, which Alticor would market to consumers through its channels under Alticor's GENSONA brand. The GENSONA Heart Health Genetic Test uses SNP testing of two genes to identify persons who may have an over-expression of inflammation and therefore may be at risk for cardiovascular disease. The GENSONA General Nutrition Genetic Test identifies SNPs of potential importance in two genes that affect vitamin B metabolism and four genes involved in responding to oxidative stress. The GENSONA tests are marketed through the Alticor business channel. Interleukin Genetics Brand of Genetic Tests: The company out-licenses sales and marketing of its Periodontal Susceptibility Test (PST). PST is a genetic test that analyzes two IL-1 genes for variations that identify an individual's predisposition for over-expression of inflammation and risk for periodontal disease. It markets and distributes its PST tests through sales and marketing partners directly to dentists and periodontists. Nutritional Supplements The company's subsidiary, the Alan James Group, develops, markets, and sells nutritional products into retail consumer channels. It has a portfolio of branded nutritional supplements which are distributed at discount retailers, drugstores, grocery stores, and warehouse clubs in the United States. The company markets and sells a line of branded nutritional supplements to major discount retailers, drugstores, grocery stores and warehouse clubs in the United States. Its portfolio includes items in multiple segments, including energy, memory, leg vein health, and heart health. Primary brand names include Ginsana, Ginkoba, Venastat, Ginsana Gold Multiplex, Optiform SAM-e, and Cransana, which are company-owned, and Kyolic, which is marketed under a distribution agreement. In addition, the company markets a line of private label skincare products to nutrition based retailer. Product Development The company intends to develop products in two categories, including genetic risk assessment tests, which identify healthy individuals who are at risk for early or severe health risks; and nutritional supplements, which support individuals seeking a healthy lifestyle in terms of energy, memory, and health. Genetic Test Product Pipeline: The company's genetic test product pipeline includes weight management genetic test; obesity management genetic test; osteoarthritis genetic test; osteoporosis genetic test; IL-1 cardiovascular genetic test; and periodontal disease genetic test (version 2.0). Weight Management and Obesity Management Tests: The company has two weight management test products under development. Both involve genetic test panels that include both proprietary and public SNPs. The first is a weight management (WM) test panel designed to assist consumers in management of body weight by guiding diet and exercise programs based on genetic differences in metabolism and fat absorption. The second program in the weight management area involves a genetic test to assist with medical and surgical management of obese individuals. The company has proprietary genetic tests that have been shown in multiple studies to predict which obese patients were resistant to weight loss when placed on a medically supervised calorie-restricted diet. The company is collaborating with the Geisinger Institute, a hospital for medical and surgical management of obesity, to validate its genetic test panel for management of weight loss in obese patients. Osteoarthritis Test: The company's Osteoarthritis (OA) program plans to investigate together with other inflammatory gene variations is associated with the occurrence of multijoint OA for the development of a genetic risk assessment test. Osteoporosis Test: The company is developing an osteoporosis risk assessment test that combines the IL-1 SNPs with SNPs in other genes known to be associated with bone loss to form a test panel. IL-1 Cardiovascular Test: The IL-1 cardiovascular genetic test is based on data from genetic association studies obtained through collaborations with experts in cardiovascular disease at academic institutions. This genetic test provides risk information independent of traditional risk factors, including family history, hypertension and smoking, in assessing risk for heart disease. General Nutrition Test: The company's general nutrition genetic test analyzes variations in various genes that influence how the body uses certain vitamins and micronutrients. The test identifies individuals who may have altered B vitamin dependent metabolism or reduced response to oxidative stress. It analyzes two genes important to B vitamin utilization and four genes important in managing oxidative stress. Collaboration The company has entered into research collaboration with Access Business Group International LLC (ABG), a subsidiary of Alticor Inc. The research agreement encompasses four primary areas; osteoporosis, cardiovascular disease, nutrigenomics, and dermagenomics. Partnerships with Academic Researchers The company has research collaborations at the University of Sheffield (UK), Tufts University, New York University, Harvard University, the Mayo Clinic, California Pacific Medical Center, Boston University, the University of Arkansas, Tongji Medical College (China), University of North Carolina, and Yonsei University (Korea). History Interleukin Genetics, Inc. was founded in 1986.
About BUYINS.NET
WWW.BUYINS.NET is a service designed to help bonafide shareholders of publicly traded US companies fight naked short selling. Naked short selling is the illegal act of short selling a stock when no affirmative determination has been made to locate shares of the stock to hypothecate in connection with the short sale. Buyins.net has built a proprietary database that uses Threshold list feeds from NASDAQ, AMEX and NYSE to generate detailed and useful information to combat the naked short selling problem. For the first time, actual trade by trade data is available to the public that shows the attempted size, actual size, price and average value of short sales in stocks that have been shorted and naked shorted. This information is valuable in determining the precise point at which short sellers go out-of-the-money and start losing on their short and naked short trades.
BUYINS.NET has built a massive database that collects, analyzes and publishes a proprietary SqueezeTrigger for each stock that has been shorted. The SqueezeTrigger database of nearly 2,650,000,000 short sale transactions goes back to January 1, 2005 and calculates the exact price at which the Total Short Interest is short in each stock. This data was never before available prior to January 1, 2005 because the Self Regulatory Organizations (primary exchanges) guarded it aggressively. After the SEC passed Regulation SHO, exchanges were forced to allow data processors like Buyins.net to access the data.
The SqueezeTrigger database collects individual short trade data on over 7,000 NYSE, AMEX and NASDAQ stocks and general short trade data on nearly 8,000 OTCBB and PINKSHEET stocks. Each month the database grows by approximately 50,000,000 short sale transactions and provides investors with the knowledge necessary to time when to buy and sell stocks with outstanding short positions. By tracking the size and price of each montha�s short transactions, BUYINS.NET provides institutions, traders, analysts, journalists and individual investors the exact price point where short sellers start losing money and a short squeeze can begin.
All material herein was prepared by BUYINS.NET, based upon information believed to be reliable. The information contained herein is not guaranteed by BUYINS.NET to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. Occassionally companies or third parties pay $995 per month to purchase data for information provided in monthly reports. The data service can be cancelled at any time. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. BUYINS.NET is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. BUYINS.NET will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.
BUYINS.NET and SQUEEZETRIGGER are intended for use by stock market professionals. As a member, visitor, or user of any kind, you accept full responsibilities for your investment and trading actions. The contents of BUYINS.NET, including but not limited to all implied or expressed views, opinions, teachings, data, graphs, opinions, or otherwise are not predictions, warranty, or endorsements of any kind. Please seek stock market advice from the proper securities professional, or investment advisor. By visiting BUYINS.NET or using any data or services, you agree to assume full responsibility for the decisions or actions that you undertake. BUYINS.NET, LLC, its owner(s), operators, employees, partners, affiliates, advertisers, information providers and any other associated person or entity, shall under no circumstances be held liable to the user and/or any third party for loss or damages of any kind, including but not limited to trading losses, lost trading opportunity, direct, indirect, consequential, special, incidental, or punitive damages. As a user, you agree that any damages collected shall not exceed the amount paid to BUYINS.NET and/or its owners. As a website user, you agree that any and all legal matters of any kind are to be reviewed and handled in their entirety within the State of California only. By using the services of this website, you are consenting to the terms as outlined, and forfeit all legal jurisdictions in any other State. Past performance is not a guarantee of future outcomes. Any and all examples are hypothetical and should not be considered a guarantee or endorsement of such trading activity. BUYINS.NET does not take responsibility for problems of any kind, including but not limited to issues with operations, data accuracy or completeness, contacting issues, technical issues, and timeliness. BUYINS.NET places great integrity on the data collected and distributed. This information is deemed reliable, but not guaranteed. All information and data is provided "as is" without warranty or guarantee of any kind.
Please seek investment and/or trading advice, council, information or services from a securities professional. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and BUYINS.NET undertakes no obligation to update such statements.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the SEC.
Contact: Thomas Ronk, CEO www.BUYINS.net +1-800-715-9999 Tom@buyins.net
